Compare PUBM & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | VALN |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.5M | 495.5M |
| IPO Year | 2020 | 2021 |
| Metric | PUBM | VALN |
|---|---|---|
| Price | $17.86 | $5.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $12.43 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 410.7K | 21.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,926,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $7.86 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.15 | $4.75 |
| 52 Week High | $14.04 | $12.25 |
| Indicator | PUBM | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 52.41 |
| Support Level | $12.84 | $5.10 |
| Resistance Level | $14.01 | $5.52 |
| Average True Range (ATR) | 0.51 | 0.13 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 73.84 | 71.68 |
PubMatic Inc is is an independent, artificial intelligence-powered advertising technology company that delivers digital advertising performance. Its integrated technology platform connects buyers, publishers, data providers, and commerce media networks on a single, unified platform, to deliver advertising performance, control, transparency and efficiency. Its platform empowers the world's digital content creators (publishers) to maximize monetization of their advertising inventory and audiences and provides control and transparency to buyers, which includes advertisers, agencies, agency trading desks, and demand side platforms (DSPs) (referred as buyers). Geographically, the company generates the majority of its revenue from the United States, followed by EMEA, APAC, and Rest of the World.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.